Compare Bristol-Myers Squibb Co (BMY) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Gigacloud Technology Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.94 (market cap $129.94B), while Gigacloud Technology Inc trades at $51.14 (market cap $1.84B). The key difference: Bristol-Myers Squibb Co is far larger — about 70.6× Gigacloud Technology Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| BMY | GCT | |
|---|---|---|
Market Cap | $129.94B | $1.84B |
Sector | Health | Technology |
52-Week High | $65.89 | $53.25 |
52-Week Low | $42.60 | $25.44 |
Enterprise Value | $163.92B | $1.97B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
GCT trades at $51.25, down 0.78% on the day, with strong technical momentum showing bullish moving averages and key resistance at $53. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.16 beating estimates by 29%, maintaining consistent earnings beats and 10.65% net margins. Revenue growth accelerated to 28% in Q2 2026, reaching $1.5B annually, while cash flow generation remains healthy at $120M net cash flow for 2025.
GCT presents a compelling growth story with attractive valuation at 12.25 P/E ratio and strong analyst support (67% buy ratings). Key risks include competitive pressures in furniture logistics and potential margin compression from expansion costs. The stock's technical overbought condition (RSI above 84) suggests near-term consolidation may precede further upside driven by execution on European expansion and New Classic integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
